Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.40 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | IL18 | Q14116 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19283732 | 1.00 | MAPT (0.56) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL15309841 | 1.00 | MAPT (0.56) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL15309839 | 1.00 | MAPT (0.56) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL29488444 | 1.00 | MAPT (0.56) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL29092415 | 0.92 | MAPT (0.52) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL617627 | 0.90 | P2RY1 (0.49) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL1117478 | 0.90 | P2RY1 (0.49) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL29364764 | 0.90 | P2RY1 (0.49) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL27082 | 0.90 | P2RY1 (0.49) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL28326410 | 0.89 | MAPT (0.47) | MAPTMEN1KMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250280829-A1 | USE OF (5S)-3-[3-(3-CHLORO-2-FLUOROPHENOXY)-6-METHYLPYRIDAZIN-4-YL]-5-(2-CHLORO-4-METHYLBENZYL)-5,6-DIHYDRO-4H-1,2,4-OXADIAZINE FOR CONTROLLING UNWANTED MICROORGANISMS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-09-11 | — | — | US | disclosed |
| US-20250228243-A1 | METHODS AND COMPOSITIONS FOR PPO HERBICIDE TOLERANCE | MONSANTO TECHNOLOGY LLC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250212874-A1 | METHODS AND COMPOSITIONS FOR CONTROLLING PESTS | GLOBACHEM NV (BE) | 2025-07-03 | — | — | US | disclosed |
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-04-24 | — | — | US | disclosed |
| US-20250127162-A1 | METHODS AND COMPOSITIONS FOR CONTROLLING PESTS IN RICE | GLOBACHEM NV (BE) | 2025-04-24 | — | — | US | disclosed |
| US-20250127163-A1 | METHODS AND COMPOSITIONS FOR CONTROLLING PESTS IN SOYBEAN | GLOBACHEM NV (BE) | 2025-04-24 | — | — | US | disclosed |
| EP-3419418-B1 | SOLVENT-FREE FORMULATIONS COMPRISING CRYSTALLINE MEFENPYR-DIETHYL | BAYER CROPSCIENCE AG (DE) | 2025-01-08 | — | — | EP | disclosed |
| EP-4139304-A1 | 2-(HET)ARYL-SUBSTITUTED CONDENSED HETEROCYCLIC DERIVATIVES AS PEST CONTROL AGENTS | Bayer Aktiengesellschaft (DE) | 2023-03-01 | — | — | EP | disclosed |
| EP-4068968-A1 | HIGHLY EFFECTIVE FORMULATIONS ON THE BASIS OF 2-[(2,4-DICHLORPHENYL)-METHYL]-4,4'-DIMETHYL-3-ISOXAZOLIDINONES AND PREEMERGENCE HERBICIDES | Bayer Aktiengesellschaft (DE) | 2022-10-12 | — | — | EP | disclosed |
| EP-4055010-A1 | SUBSTITUTED SULFONYL AMIDES FOR CONTROLLING ANIMAL PESTS | Bayer Aktiengesellschaft (DE) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228243-A1 | METHODS AND COMPOSITIONS FOR PPO HERBICIDE TOLERANCE | UNG, PNPO, PPOX | MAPT 3295/4885MEN1 4875/4885KMT2A 2808/4885 |
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | RECQL, QTRT2, NQO2 | MAPT 3341/4885MEN1 994/4885KMT2A 1446/4885 |
| US-20250280829-A1 | USE OF (5S)-3-[3-(3-CHLORO-2-FLUOROPHENOXY)-6-METHYLPYRIDAZIN-4-YL]-5-(2-CHLORO-4-METHYLBENZYL)-5,6-DIHYDRO-4H-1,2,4-OXADIAZINE FOR CONTROLLING UNWANTED MICROORGANISMS | CYP4Z1, IL5, NT5C | MAPT 2680/4885MEN1 3661/4885KMT2A 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.